Danny Rischin, Sandro V. Porceddu, Fiona Day, Daniel Brungs, Hayden Robert Christie, James Estes Jackson, Brian N. Stein, Annette May Ling Lim, Yungpo Su, Samantha Bowyer, Naoya Yamazaki, Paolo Bossi, Armarnath Challapalli, Rahul Ladwa, Axel Hauschild, Debra AG McIntyre, Frank A. Seebach, Suk-Young Yoo, Priscila Hermont Goncalves, Matthew G. Fury. "C-POST study of adjuvant cemiplimab for high-risk cutaneous squamous cell carcinoma (CSCC): Disease-free survival (DFS) analyses per high-risk criteria and per start time after radiotherapy.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.6083